Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?

Pfizer trades at a lower forward P/E ratio and AbbVie offers a higher dividend yield as both companies confront patent and pricing risks.

Summary by The Motley Fool
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

1 Articles

The Motley FoolThe Motley Fool
Lean Left

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

·Alexandria, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Motley Fool broke the news in Alexandria, United States on Friday, September 25, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

AbbVie icon

AbbVie

Johnson & Johnson icon

Johnson & Johnson

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal